
Mauritania

Parasites and vectors



I. Epidemiological profile

Population (UN Population Division)	2017	%
High transmission (>1 case per 1000 population)	2.8M	64
Low transmission (0-1 case per 1000 population)	1.6M	36
Malaria free (0 cases)	0	-
Total	4.4M	

 Major plasmodium species:
 P.falciparum: 100 (%) , P.vivax: 0 (%)

 Major anopheles species:
 An. gambiae, An. arabiensis, An. pharoensis

 Reported confirmed cases (health facility):
 20 105
 Estimated cases:
 238.3K [94.7K, 445.1K]

 Confirmed cases at community level:

 Confirmed cases from private sector:

 Reported deaths:
 67
 Estimated deaths:
 1.5K [1.3K, 1.7K]

II. Intervention policies and strategies

Policies/Strategies ITNs/LLINs distributed free of charge	No	adopted
ITNs/LLINs distributed free of charge		
	Yes	1998
ITNs/LLINs distributed to all age groups	Yes	-
IRS is recommended	Yes	-
DDT is used for IRS	No	=
Use of Larval Control	No	2013
IPT used to prevent malaria during pregnancy	Yes	2008
Patients of all ages should receive diagnostic test	Yes	2011
Malaria diagnosis is free of charge in the public sector	Yes	2009
ACT is free for all ages in public sector	Yes	2009
The sale of eral artemisinin based manetheranies (eAMTr)	is	
The sale of oral artemisinin-based monotherapies (OAMTS)		-
Single dose of primaquine (0.25 mg base/kg) is used as	Nο	-
	.,,	
Primaquine is used for radical treatment of P. vivax	Yes	2014
G6PD test is a requirement before treatment with primaquine	Yes	2014
Directly observed treatment with primaquine is undertaken	No	-
System for monitoring of adverse reaction to antimalarials exists	Yes	2009
ACD for case investigation (reactive)	-	-
ACD at community level of febrile cases (pro-active)	-	-
Mass screening is undertaken	Yes	-
Uncomplicated P. falciparum cases routinely admitted	Yes	-
Uncomplicated P. vivax cases routinely admitted	Yes	-
Case and foci investigation undertaken	No	
Case reporting from private sector is mandatory	Yes	2014
	DDT is used for IRS Use of Larval Control IPT used to prevent malaria during pregnancy Patients of all ages should receive diagnostic test Malaria diagnosis is free of charge in the public sector ACT is free for all ages in public sector The sale of oral artemisinin-based monotherapies (oAMTs) Single dose of primaquine (0.25 mg base/kg) is used as gametocidal medicine for P. falciparum Primaquine is used for radical treatment of P. vivax G6PD test is a requirement before treatment with primaquine Directly observed treatment with primaquine is undertaken System for monitoring of adverse reaction to antimalarials exists ACD for case investigation (reactive) ACD at community level of febrile cases (pro-active) Mass screening is undertaken Uncomplicated P. falciparum cases routinely admitted Uncomplicated P. vivax cases routinely admitted Case and foci investigation undertaken	DDT is used for IRS Use of Larval Control IPT used to prevent malaria during pregnancy Patients of all ages should receive diagnostic test Malaria diagnosis is free of charge in the public sector ACT is free for all ages in public sector The sale of oral artemisinin-based monotherapies (oAMTs) Single dose of primaquine (0.25 mg base/kg) is used as gametocidal medicine for P. falciparum Primaquine is used for radical treatment of P. vivax Yes G6PD test is a requirement before treatment with primaquine Directly observed treatment with primaquine is undertaken No System for monitoring of adverse reaction to antimalarials exists ACD for case investigation (reactive) ACD at community level of febrile cases (pro-active) Mass screening is undertaken Uncomplicated P. falciparum cases routinely admitted Yes Uncomplicated P. vivax cases routinely admitted Yes Case and foci investigation undertaken No

Antimalaria	a treatment po	licy				Medicine	Year adopted
First-line treatment of unconfirmed malaria			AS+AQ	=			
First-line treatment of P. falciparum				AL; AS+AQ	-		
For treatment failure of P. falciparum				-	-		
Treatment of severe malaria				QN	-		
Treatment	of P. vivax					-	-
Dosage of	primaquine fo	r radical	treatme	nt of P. vi	vax	0.25 mg	g/Kg (14 days)
Type of RD	of RDT used		P.f + P.v s	pecific (Combo)			
Theraneuti	ic efficacy tests	s (clinical	and nar	asitologi	cal failure	%)	
Medicine	Year	`	1edian		ollow-up	No. of studies	Species
AS+AO	2012-2012	1.8	1.8	1.8	28 days	2	P. falciparum
co	2012-2012	0	0	0	28 days	2	P. vivax
Resistance	ctatus by inco	cticido cl	acc /201	0-2017)	and use of a	class for malaria vec	tor control (201
Insecticide		Years			sites ¹	Vectors ²	Used ³
Carbamates		2015	-2015	0% (-	No
Organochlo	rines			-	- 7	-	No
Organophos	sphates	2015	-2015	0% (2)	-	No
		2015	-2015	66.6	7% (3)	An. gambiae s.l.	Yes
Pyrethroids			c	d total num	her of sites th	nat reported data (n)	
	ites for which resi	istance con					
¹ Percent of s	ites for which resi			a total nun		, , , ,	